Exelixis, Inc. Share Price & Technical Analysis
EXEL · $50.95 (-0.66%)
Healthcare / Biotechnology
$50.95
-0.66%
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroi…
Price chart
Seasonality
May has 4 positive and 1 negative years (last 5 years shown)
14% return in May, 5% avg return in past 3 year May month.
20% return in 2026, 43% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -5% | 5% | 2% | 3% | 14% | – | – | – | – | – | – | – | 20% |
| 25 | -1% | 18% | -5% | 7% | 10% | 1% | -18% | 3% | 11% | -6% | 18% | 0% | 38% |
| 24 | -9% | 0% | 8% | 0% | 0% | 4% | 5% | 11% | 0% | 28% | 9% | -9% | 48% |
| 23 | 10% | -2% | 13% | -6% | 5% | -2% | 4% | 14% | -3% | -6% | 6% | 10% | 43% |
| 22 | -1% | 13% | 11% | -2% | -18% | 14% | 0% | -16% | -11% | 4% | 1% | -6% | -10% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Strong · Strong
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent oral inhibitor of kinases, including the TAM kinases, MET, and VEGF receptors; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an antibody-drug conjugates (ADC) consisting of a MMAE payload conjugated to a monoclonal antibody targeting the tumor antigen 5T4; XB628, a first-in-class bispecific antibody that targets programmed cell death ligand 1and natural killer cell receptor group 2A; and XB371, a next-generation tissue factor targeting ADC with a topoisomerase inhibitor payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent, Inc.; Iconic Therapeutics, Inc.; Adagene Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as business development activities and other collaborations. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$12.48B
P/E ratio
16.44
52W high
$51.63
52W low
$33.76
Volume
10,77,850
Beta
0.39
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Exelixis, Inc. share price today?
- Exelixis, Inc. (EXEL) last traded around $50.95 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does EXEL have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for EXEL. Download the app for real-time alerts.
- How can I analyze Exelixis, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.